InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (10 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
10
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the detailed record of transactions filed by Rolph Timothy, Chief Scientific Officer. Officer active across 1 company, notably Akero Therapeutics, Inc.. In total, 34 filings have been logged. Split: 0 buy · 10 sells. Total volume traded: €1m. Activity tracked since 30 June 2022. The latest transaction was filed on 6 May 2025 (Levée d'options). Regulator: SEC (Form 4). The full history is free.
Declarations34 total
238,339 sharesCommon StockSEC:0001193125-25-312116
238,339 sharesCommon StockSEC:0001193125-25-312116:0
43,810 sharesCommon StockSEC:0001193125-25-312116:1
12,500 shares@ US$21.107.8% of flowCommon StockSEC:0000950170-25-067381:0
6,250 shares@ US$21.103.9% of flowCommon StockSEC:0000950170-25-059449:0
6,250 shares@ US$21.104.0% of flowCommon StockSEC:0000950170-25-052956:0
516 shares@ US$44.880.7% of flowCommon StockSEC:0000950170-25-039731:0
12,500 shares@ US$21.108.3% of flowCommon StockSEC:0000950170-25-035709:0
18,750 shares@ US$21.1012.8% of flowCommon StockSEC:0000950170-25-016493:0
14,986 shares@ US$19.879.5% of flowCommon StockSEC:0000950170-25-010707:0
14,000 shares0Common StockSEC:0000950170-25-004425:0
14,100 shares0Common StockSEC:0000950170-24-141259:0
3,800 shares@ US$19.872.4% of flowCommon StockSEC:0000950170-24-138134:0
2,368 shares@ US$30.792.3% of flowCommon StockSEC:0000950170-24-136025:0
537 shares@ US$26.180.4% of flowCommon StockSEC:0000950170-24-106458:0
1,064 shares@ US$19.9410.7% of flowCommon StockSEC:0000950170-24-080926:0
2,380 shares@ US$22.6411.7% of flowCommon StockSEC:0000950170-24-073185:0
619 shares@ US$28.330.5% of flowCommon StockSEC:0000950170-24-032261:0
514 shares@ US$20.760.3% of flowCommon StockSEC:0000950170-23-071236:0
32,497 shares0Common StockSEC:0000950170-23-069753:0
531 shares@ US$50.341.9% of flowCommon StockSEC:0000950170-23-049764:0
40,000 shares@ US$0.610.7% of flowCommon StockSEC:0000950170-23-029227:0
509 shares@ US$55.160.9% of flowCommon StockSEC:0000899243-23-015670:0
603 shares@ US$43.470.8% of flowCommon StockSEC:0000899243-23-008401:0
1,700 shares@ US$28.351.5% of flowCommon StockSEC:0000899243-22-039574:0
25 of 34 declarations
About Rolph Timothy
Timothy Rolph is the Chief Scientific Officer at Akero Therapeutics, Inc. He oversees research and development initiatives, ensuring innovation in the development of new treatments. His role is essential for the scientific advancement of the company.
